BIOPOR Bioporto A/S

Rights issue fully subscribed

Rights issue fully subscribed

April 6, 2020

Announcement no. 8

Rights issue fully subscribed

By company announcement no. 6 of March 16, 2020, BioPorto A/S (“BioPorto”) announced the initiation of a right issue (the “Offering”) with pre-emptive subscription rights for the Company’s existing shareholders allowing for subscription of up to 24,992,054 new shares with a nominal value of DKK 1 each (the “New Shares”).

The subscription period for the New Shares has expired, and BioPorto is pleased to announce that all of the New Shares have been subscribed for. The offering is thus fully subscribed for.

The allocation of subscription orders for remaining shares will be communicated to the individual investors in due course.

The Offering will be completed when payment of subscription amounts have taken place and the New Shares have been registered with the Danish Business Authority, expectedly on April 14, 2020. The expected timetable in BioPorto’s company announcement no. 6 of March 16, 2020 remains unchanged.

Yours sincerely

BioPorto A/S

For further information, please contact:

Peter Mørch Eriksen, CEO

Ole Larsen, CFO

Telephone , e-mail:

About BioPorto

BioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].

Attachment

EN
06/04/2020

Underlying

BIOPORBioporto A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioporto A/S

 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voks...

BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off 31. marts, 2026Meddelelse no. 6 BioPorto indsender anmodning om FDA pre‑submission for amerikansk voksenprogram for urin‑NGAL efter positiv EPACRA‑analyse af AKI‑cut‑off KØBENHAVN, DANMARK, 31. marts, 2026 – BioPorto A/S ("BioPorto" eller "Selskabet") (CPH: BIOPOR) meddelte i dag, at de formelt har indsendt deres FDA Pre-submission pakke til den amerikanske Food and Drug Administration (FDA). Dette markerer en vigtig regulatorisk milepæl for Selskabet ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submissio...

BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis March 31, 2026Announcement no. 6 BioPorto Advances U.S. Adult Urine NGAL Program with FDA Pre-Submission Request After Positive EPACRA AKI Cut Off Analysis COPENHAGEN, DENMARK, 31 March 2026 – BioPorto A/S (“BioPorto” or “Company”) (CPH: BIOPOR) today announced that it has formally submitted its FDA pre‑submission package to the U.S. Food and Drug Administration (FDA). This marks an important regulatory milestone for the Company and follows the positive preliminary an...

March 31, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Indkaldelse til ordinær generalforsamling i BioPorto A/S

Indkaldelse til ordinær generalforsamling i BioPorto A/S 26. marts 2026Selskabsmeddelelse nr. 5 Indkaldelse til ordinær generalforsamling i BioPorto A/S Bestyrelsen indkalder hermed til ordinær generalforsamling i BioPorto A/S ("BioPorto" eller "Selskabet"), som afholdes: 24. april 2026 kl. 15.00på Selskabets adresseTuborg Havnevej 15, st., 2900 Hellerup, Danmark DAGSORDEN: PUNKT 1 - BERETNING OM SELSKABETS VIRKSOMHED I DET FORLØBNE ÅR Bestyrelsen foreslår, at bestyrelsens beretning om Selskabets virksomhed i det forløbne år tages til efterretning. PUNKT 2 – FREMLÆGGELSE AF ÅRSRAPP...

March 26, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

Notice convening the Annual General Meeting in BioPorto A/S

Notice convening the Annual General Meeting in BioPorto A/S 26 March 2026Announcement no. 5 Notice convening the Annual General Meeting in BioPorto A/S The Board of Directors hereby convenes the Annual General Meeting of BioPorto A/S (“BioPorto” or the “Company”) to be held on: 24 April 2026 at 3.00 p.m. (CEST)at the Company’s addressTuborg Havnevej 15, st., DK-2900 Hellerup, Denmark AGENDA: ITEM 1 - REPORT ON THE COMPANY’S ACTIVITIES DURING THE PAST YEAR The Board of Directors proposes that the Board's report on the Company’s activities for the past year be noted. ITEM 2 – PRESENT...

March 26, 2026 1 EN
 PRESS RELEASE
Free
BIOPOR BIOPORTO A/S

BioPorto annoncerer Årsrapporten for 2025

BioPorto annoncerer Årsrapporten for 2025 26. marts 2026Meddelelse nr. 04                                                                                                                                                                                                BioPorto annoncerer årsrapporten for 2025 København, Danmark, 26. marts 2026 (GLOBE NEWSWIRE) – BioPorto A/S CVR-nr. 17500317 (BioPorto eller selskab) (CPH:BIOPOR) offentliggjorde i dag de finansielle resultater for året 2025. De finansielle resultater for 2025 bekræfter de foreløbige, ureviderede finansielle tal for 202...

March 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch